Multi-omics analysis identifies COX6A2/SCF/c-Kit-mediated mitochondrial remodeling as a key mechanism of Tangwei’an decoction in diabetic gastroparesis

Figure 2 Tangwei’an alleviates pathological injury and improves gastrointestinal motility in diabetic gastroparesis mice. A: Experimental workflow of the diabetic gastroparesis model and treatment procedure; B: Fasting blood glucose levels of mice at different time points (n = 7-9); C: Body weight of mice at different time points (n = 7-9); D: Representative photographs of mice from each experimental group; E: Gastric emptying rate of each group (n = 7-9); F: Intestinal transit rate of each group (n = 7-9); G: Hematoxylin & eosin staining of gastric tissues in each group. Scale bar = 100 μm; H: Gastric histopathological score (n = 3); I: Hematoxylin & eosin staining of colonic tissues in each group. Scale bar = 100 μm; J: Colonic histopathological score (n = 3); K: Serum levels of Motilin, serotonin, substance P, cholecystokinin, and vasoactive intestinal peptide in mice (n = 7-9). Data are presented as the means ± SEM. ^aP < 0.05 vs Control group, ^bP < 0.01 vs Control group, ^cP < 0.05 vs the Model group, ^dP < 0.01 vs the Model group. TWA-H: Tangwei’an decoction high-dose group; TWA-M: Tangwei’an decoction medium-dose group; TWA-L: Tangwei’an decoction low-dose group; 5-HT: Serotonin; SP: Substance P; CCK: Cholecystokinin; VIP: Vasoactive intestinal peptide.